Article

Dr. Pierce joins MEEI

in September, clinician scientist Eric Pierce, MD, PhD, will join in September the Massachusetts Eye and Ear Infirmary and Harvard Department of Ophthalmology. Dr. Pierce will serve as associate director of the Berman-Gund Laboratory for the Study of Retinal Degenerations as a clinician and educator, and as director of the new Ocular Genomics Institute, where he will direct the genetic therapies program..

Boston-In September, clinician scientist Eric Pierce, MD, PhD, will join the Massachusetts Eye and Ear Infirmary (MEEI) and Harvard Department of Ophthalmology.

Dr. Pierce will serve as associate director of the Berman-Gund Laboratory for the Study of Retinal Degenerations as a clinician and educator, and as director of the new Ocular Genomics Institute, where he will direct the genetic therapies program.

Dr. Pierce’s scientific efforts to date have included groundbreaking work to address retinal degenerations using genetic sequencing and gene therapy methods. His recent research efforts have focused on the use of next-generation DNA sequencing to identify retinal degeneration genes, and to improve genetic diagnostic testing for patients who have inherited retinal degeneration disorders.

“I take extraordinary pride in welcoming Dr. Pierce, who is one of the preeminent clinician scientists in this important field of ophthalmic disease and research,” said Joan W. Miller, MD, chief of ophthalmology at Massachusetts Eye and Ear and Massachusetts General Hospital, and chair of ophthalmology at Harvard Medical School. “Bringing him into the department will accelerate our growth into advanced studies in genomic research and gene therapy, and move us another critical step closer to achieving our mission of eliminating blinding diseases,” she said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.